Ray Sumita
Known title: Chief Legal Compliance OfficerCIK: 0001579629
Associated companies
Transaction History
| CUE | ▲ Buy | Option Exercise | 18,196 | $0 | 8/13/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 2,383 | $70K | 8/13/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 6,442 | $196K | 8/13/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 4 | $125 | 8/13/2026 | View on chart |
| CUE | ▲ Buy | Grant | 54,589 | $0 | 7/9/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.